arrow
E

Ezra Y. Rosen

Memorial Sloan Kettering Cancer Center
H指数:18
被引数:3,178

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The cold immunological landscape of ATM-deficient cancers

ATM缺陷型癌症的冷免疫景观

2025-05-110
OA
Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors

CFT1946的I期研究初步结果,CFT1946是一种新型BIDAC降解剂,用于突变型BRAF V600实体瘤。

2024-09-012
PRE
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
2024-06-260
PRE
A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab
2024-06-010
PRE
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
2024-05-062
OAAI
Benralizumab for treatment of eosinophil-related cutaneous adverse events associated with checkpoint inhibitors and anticancer targeted therapies: Phase 2 study
2024-03-220
PRE
Identification of monoallelic ATM loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy
2024-01-090
PRE
Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
2023-12-010
PRE
Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials
2023-12-010
PRE